Hydroxymethylaryl-substituted pyrrolotriazines as ALK1 inhibitors

US9040691B2 · kind B2 · utility

Assignee

• Bayer Intellectual Property GmbH · DE

Inventors

• Jürgen Klar · Wuppertal, DE
• Verena Vöhringer · Wuppertal, DE
• Joachim Telser · Wuppertal, DE
• Mario Lobell · Wuppertal, DE
• Frank Süβmeier · Birkenfeld, DE
• Volkhart Min-Jian Li · Velbert, DE
• Michael Bottger · Wuppertal, DE
• Stefan Golz · Wetter (Ruhr), DE
• Dieter Lang · Velbert, DE
• Karl-Heinz Schlemmer · Wuppertal, DE
• Thomas Schlange · Haan, DE
• Andreas Schall · Wuppertal, DE
• Wenlang Fu · Milford, US

Key dates

• Filing date: Jun 26, 2012
• Grant date: May 26, 2015
• Expiry date: Jun 26, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to novel 5-[(hydroxymethyl)aryl]-substituted pyrrolo[2,1-f][1,2,4]triazin-4-amines of formula (I), to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for treating angiogenesis-related disorders, in particular angiogenesis-related ocular disorders.